Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561284 | 0.93 | HTT (0.64) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL16960801 | 0.90 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.89 | SMN1; SMN2 (0.60) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL8762477 | 0.88 | HTT (0.59) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL7137680 | 0.87 | ALDH1A1 (0.66) | HTTSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL38446 | 0.86 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL583563 | 0.86 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL8501501 | 0.85 | ALDH1A1 (0.63) | HTTSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL8501497 | 0.85 | ALDH1A1 (0.63) | HTTSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL231014 | 0.85 | SMN1; SMN2 (0.57) | HTTSMN1; SMN2GAAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008054454-A2 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF AS ANTIVIRAL AGENTS | TRANSTECH PHARMA, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008054454-A2 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF AS ANTIVIRAL AGENTS | TRANSTECH PHARMA, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
| US-6630496-B1 | Antiinflammatory agents inhibit phospholipase 2, affecting both protaglandin and leukotriene production; indoles substituted in 2 position by 2,4-dioxo-thiazol-3-yl methylidene | GENETICS INSTITUTE LLC | 2003-10-07 | — | — | US | disclosed |
| CN-1298404-A | Inhibitors of phospholipase A2 | GENETICS INST (US) | 2001-06-06 | — | — | CN | disclosed |
| EP-1062216-A1 | INHIBITORS OF PHOSPHOLIPASE A2 | GENETICS INSTITUTE, INC. (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999043672-A9 | INHIBITORS OF PHOSPHOLIPASE A2 | GENETICS INST (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999043672-A1 | INHIBITORS OF PHOSPHOLIPASE A2 | GENETICS INSTITUTE, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0922028-A1 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998008818-A1 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NUDT1, PNP, NME2 | HTT 2061/4885SMN1; SMN2 2041/4885GAA 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.